+1 (704) 266-3234

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Pipeline Review H1 2017

Published on: Jun 2017 | From USD $2500 | Published By: GMD | Number Of Pages: 137

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Review, H1 2017, provides an overview of the Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline landscape.

Malignant peripheral nerve sheath tumors (MPNSTs) are sarcomas which originate from peripheral nerves or from cells associated with the nerve sheath, such as Schwann cells, perineural cells, or fibroblasts. Symptoms include lump or swelling in the in the soft tissue, numbness, burning or having that pins and needles feeling, weakness in the affected muscles and dizziness or loss of balance. Treatment includes surgery, radiotherapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 7 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Overview
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Companies Involved in Therapeutics Development
Bexion Pharmaceuticals LLC
EpiZyme Inc
Merck & Co Inc
Millennium Pharmaceuticals Inc
Novartis AG
Pfizer Inc
Plexxikon Inc
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Drug Profiles
axitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BXQ-350 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
everolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ganetespib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oncolytic Virus to Target CD46 and SLC5A5 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pembrolizumab - Drug Profile
R&D Progress
pexidartinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sapanisertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit BRD4 for Malignant Peripheral Nerve Sheath Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tazemetostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Product Development Milestones
Featured News & Press Releases
Dec 26, 2013: UTSW study identifies potential therapeutic target for incurable, rare type of soft-tissue cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Bexion Pharmaceuticals LLC, H1 2017
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by EpiZyme Inc, H1 2017
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Merck & Co Inc, H1 2017
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Novartis AG, H1 2017
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Pfizer Inc, H1 2017
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Plexxikon Inc, H1 2017 List of Figures
Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Please Choose License Type

USD $2500
USD $5000
USD $7500
Offer

Why Us

  • Why Us In-depth database
    Our Report’s database covers almost all topics of all regions over the Globe..
  • Why Us Recognised publishing sources
    Tie ups with top publishers around the globe.
  • Why Us Customer Support
    Complete pre and post sales support.
  • Why Us Safe & Secure
    Complete secure payment process.